amfAR Statement on Biden-Harris Rule Changes Regarding Insurance Coverage for Long-Acting PrEP and Contraceptives
amfAR Praises PEPFAR Reauthorization, Yet Concerns Over One-Year Authorization and Implications for U.S. Global Health Leadership Remain